HER2-Negative Breast Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and

HER2-Negative Breast Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)


The battle against cancer continues, with HER2 negative breast cancer being a prominent focus in the fight against this formidable disease. A recent report sheds light on the state of the global HER2 negative breast cancer treatment market, offering critical insights into trends, therapies, and key players in this critical healthcare sector.

Understanding HER2 Negative Breast Cancer Breast cancer is a complex group of diseases characterized by the uncontrolled division of cells, forming tumors. The type of breast cancer is often named after the part of the body where the tumor originates. In the case of HER2 negative breast cancer, the tumor lacks an overexpression of the HER2 or ERBB2 gene, making it a distinct subtype.

HER2 Negative Breast Cancer Overview According to data published by ASCO (American Society of Clinical Oncology), ductal carcinomas account for approximately 75% of all breast cancer cases. These cancers originate either in the lobules or ducts of the breast. Lobular carcinoma starts in the lobules, while ductal carcinoma begins in the ducts connected to the lobules. Invasive ductal or invasive carcinoma occurs when the cancer spreads beyond these structures.

Critical Role of HER2 Testing To determine the appropriate treatment for HER2 negative breast cancer, receptor testing plays a vital role. Three common tests are employed to assess HER2 levels: chromogenic in situ hybridization (CISH), immunohistochemistry (IHC), and fluorescent in situ hybridization (FISH). Depending on the levels of HER2 in these tests, breast cancer is classified as HER2 positive or HER2 negative. HER2 is a receptor that plays a crucial role in breast cancer growth and division.

Tailored Treatment Approaches Treatment for HER2 negative breast cancer varies based on receptor status. Hormonal therapy is a key approach for HER2 negative breast cancer that is estrogen receptor (ER) positive, aiming to reduce estrogen levels or block its effects. However, for the challenging subtype of Triple Negative Breast Cancer (TNBC), where cancer cells lack estrogen, progesterone, and HER2 receptors, hormonal therapy is not effective.

Market Dynamics The global HER2 negative breast cancer treatment market is driven by the increasing incidence and prevalence of breast cancer worldwide. The pipeline of drugs for HER2 negative breast cancer and breast cancer in general also fuels market growth. However, challenges include treatment side effects like chemotherapy, the risk of tumor recurrence in many cases, and the stress and cost of multiple treatments.

Market Segmentation The HER2 negative breast cancer treatment market is segmented by treatment type into chemotherapy, radiation, surgery, and hormonal therapy. Hormonal therapy includes various approaches like Selective estrogen-receptor response modulators (SERMs), Estrogen-receptor downregulators (ERDs), Aromatase inhibitors, and Luteinizing hormone-releasing hormone agents (LHRHs).

Global Presence Geographically, the global HER2 negative breast cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Key players in this market include Array BioPharma, AstraZeneca plc., CELGENE CORPORATION, Eli Lilly and Company, Novartis AG, AbbVie Inc., Merck & Co., Inc., Pfizer Inc., and more.

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.


1. Executive Summary
1.1. Global HER2-Negative Breast Cancer Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global HER2-Negative Breast Cancer Treatment Market Outlook, 2018 – 2031
3.1. Global HER2-Negative Breast Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 – 2031
3.1.1. Key Highlights
3.1.1.1. Chemotherapy
3.1.1.2. Surgery
3.1.1.3. Radiation
3.1.1.4. Hormonal therapy/endocrine therapy
3.1.1.4.1. Selective estrogen-receptor response modulators (SERMs)
3.1.1.4.2. Estrogen-receptor downregulators (ERDs)
3.1.1.4.3. Aromatase inhibitors
3.1.1.4.4. Luteinizing hormone-releasing hormone agents (LHRHs)
3.2. Global HER2-Negative Breast Cancer Treatment Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
3.2.1. Key Highlights
3.2.1.1. North America
3.2.1.2. Europe
3.2.1.3. Asia Pacific
3.2.1.4. Latin America
3.2.1.5. Middle East & Africa
4. North America HER2-Negative Breast Cancer Treatment Market Outlook, 2018 – 2031
4.1. North America HER2-Negative Breast Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 – 2031
4.1.1. Key Highlights
4.1.1.1. Chemotherapy
4.1.1.2. Surgery
4.1.1.3. Radiation
4.1.1.4. Hormonal therapy/endocrine therapy
4.1.1.4.1. Selective estrogen-receptor response modulators (SERMs)
4.1.1.4.2. Estrogen-receptor downregulators (ERDs)
4.1.1.4.3. Aromatase inhibitors
4.1.1.4.4. Luteinizing hormone-releasing hormone agents (LHRHs)
4.1.2. BPS Analysis/Market Attractiveness Analysis
4.2. North America HER2-Negative Breast Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
4.2.1. Key Highlights
4.2.1.1. U.S. HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
4.2.1.2. Canada HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
4.2.2. BPS Analysis/Market Attractiveness Analysis
5. Europe HER2-Negative Breast Cancer Treatment Market Outlook, 2018 – 2031
5.1. Europe HER2-Negative Breast Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 – 2031
5.1.1. Key Highlights
5.1.1.1. Chemotherapy
5.1.1.2. Surgery
5.1.1.3. Radiation
5.1.1.4. Hormonal therapy/endocrine therapy
5.1.1.4.1. Selective estrogen-receptor response modulators (SERMs)
5.1.1.4.2. Estrogen-receptor downregulators (ERDs)
5.1.1.4.3. Aromatase inhibitors
5.1.1.4.4. Luteinizing hormone-releasing hormone agents (LHRHs)
5.1.2. BPS Analysis/Market Attractiveness Analysis
5.2. Europe HER2-Negative Breast Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
5.2.1. Key Highlights
5.2.1.1. Germany HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
5.2.1.2. U.K. HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
5.2.1.3. France HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
5.2.1.4. Italy HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
5.2.1.5. Turkey HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
5.2.1.6. Russia HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
5.2.1.7. Rest of Europe HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
5.2.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific HER2-Negative Breast Cancer Treatment Market Outlook, 2018 – 2031
6.1. Asia Pacific HER2-Negative Breast Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 – 2031
6.1.1. Key Highlights
6.1.1.1. Chemotherapy
6.1.1.2. Surgery
6.1.1.3. Radiation
6.1.1.4. Hormonal therapy/endocrine therapy
6.1.1.4.1. Selective estrogen-receptor response modulators (SERMs)
6.1.1.4.2. Estrogen-receptor downregulators (ERDs)
6.1.1.4.3. Aromatase inhibitors
6.1.1.4.4. Luteinizing hormone-releasing hormone agents (LHRHs)
6.1.2. Others BPS Analysis/Market Attractiveness Analysis
6.2. Asia Pacific HER2-Negative Breast Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
6.2.1. Key Highlights
6.2.1.1. China HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
6.2.1.2. Japan HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
6.2.1.3. South Korea HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
6.2.1.4. India HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
6.2.1.5. Southeast Asia HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
6.2.1.6. Rest of Asia Pacific HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
6.2.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America HER2-Negative Breast Cancer Treatment Market Outlook, 2018 – 2031
7.1. Latin America HER2-Negative Breast Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 – 2031
7.1.1. Key Highlights
7.1.1.1. Chemotherapy
7.1.1.2. Surgery
7.1.1.3. Radiation
7.1.1.4. Hormonal therapy/endocrine therapy
7.1.1.4.1. Selective estrogen-receptor response modulators (SERMs)
7.1.1.4.2. Estrogen-receptor downregulators (ERDs)
7.1.1.4.3. Aromatase inhibitors
7.1.1.4.4. Luteinizing hormone-releasing hormone agents (LHRHs)
7.1.2. BPS Analysis/Market Attractiveness Analysis
7.2. Latin America HER2-Negative Breast Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
7.2.1. Key Highlights
7.2.1.1. Brazil HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
7.2.1.2. Mexico HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
7.2.1.3. Argentina HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
7.2.1.4. Rest of Latin America HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
7.2.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa HER2-Negative Breast Cancer Treatment Market Outlook, 2018 – 2031
8.1. Middle East & Africa HER2-Negative Breast Cancer Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 – 2031
8.1.1. Key Highlights
8.1.1.1. Chemotherapy
8.1.1.2. Surgery
8.1.1.3. Radiation
8.1.1.4. Hormonal therapy/endocrine therapy
8.1.1.4.1. Selective estrogen-receptor response modulators (SERMs)
8.1.1.4.2. Estrogen-receptor downregulators (ERDs)
8.1.1.4.3. Aromatase inhibitors
8.1.1.4.4. Luteinizing hormone-releasing hormone agents (LHRHs)
8.1.2. BPS Analysis/Market Attractiveness Analysis
8.2. Middle East & Africa HER2-Negative Breast Cancer Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
8.2.1. Key Highlights
8.2.1.1. GCC HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
8.2.1.2. South Africa HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
8.2.1.3. Egypt HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
8.2.1.4. Nigeria HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
8.2.1.5. Rest of Middle East & Africa HER2-Negative Breast Cancer Treatment Market by Treatment Type, Value (US$ Bn), 2018 – 2031
8.2.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs by End User Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Pfizer
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Roche
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Astrazeneca
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Novartis
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Celgene
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Chipscreen biosciences
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. OBI Pharma
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Radius Health
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Immunomedics
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. PolyPhor
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings